Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine for Persistent Dentoalveolar Pain
NCT04207411Phase 2Unknown
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Aug 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of bupivacaine in Persistent dentoalveolar pain disorder (PDAP) (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Proportion of patients with at least 30% pain reduction at 2 months. Status: unknown.
02
Drugs
bupivacaine
03
Conditions
Persistent dentoalveolar pain disorder (PDAP)
Beyond the preview
Go deeper on NCT04207411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207411.